Johnson & Johnsonvs.Merck & Co.
JNJ vs MRK · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Johnson & Johnson is about 2.0× larger than Merck & Co. by market cap; Johnson & Johnson trades at the lower P/E (29.5 vs 34.1); year to date, Johnson & Johnson leads (+24.2% vs +17.4%).
Side by side
| JNJ | MRK | |
|---|---|---|
| Market cap | $620B | $305B |
| Price | $256.98 | $123.54 |
| Today | −0.8% | −1.2% |
| Return YTD | +24.2% | +17.4% |
| Return 1Y | +63.0% | +47.0% |
| P/E | 29.5 | 34.1 |
| P/S | 6.4 | 4.6 |
| P/B | 7.6 | 6.7 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Johnson & JohnsonJNJ
American healthcare group with a large pharmaceutical division (Innovative Medicine) and medtech division (MedTech).
Full JNJ profile →Merck & Co.MRK
American pharmaceutical group with strengths in oncology (Keytruda), vaccines and animal health.
Full MRK profile →More comparisons in Big pharma
See where JNJ and MRK sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →